Ikjae Lee, Grace Jang, Ying Kuen Ken Cheung, Alexander V Sherman, Wendy S Johnston, Frank Diaz, J Americo M Fernandes, Ali A Habib, Nicholas J Maragakis, Sabrina Paganoni, Katherine Burke, Bjorn Oskarsson, Jaimin Shah, Lorne Zinman, Mary Kay Floeter, Senda Ajroud-Driss, Kelly Gwathmey, Terry Heiman-Patterson, Omar Jawdat, Edward J Kasarskis, Yaz Y Kisanuki, James Wymer, Christina Fournier, Ghazala Hayat, Daragh Heitzman, Catherine Lomen-Hoerth, Michael T Pulley, Stephen N Scelsa, David Walk, Stephen A Goutman, Christen Shoesmith, Zachary Simmons, Eric Sorenson, Lauren Elman, Matthew B Harms, Benjamin N Hoover, Rebecca Y Yun, Regina M Santella, Hiroshi Mitsumoto
{"title":"原发性侧索硬化自然史研究:原发性侧索硬化功能评定量表和其他结果评估。","authors":"Ikjae Lee, Grace Jang, Ying Kuen Ken Cheung, Alexander V Sherman, Wendy S Johnston, Frank Diaz, J Americo M Fernandes, Ali A Habib, Nicholas J Maragakis, Sabrina Paganoni, Katherine Burke, Bjorn Oskarsson, Jaimin Shah, Lorne Zinman, Mary Kay Floeter, Senda Ajroud-Driss, Kelly Gwathmey, Terry Heiman-Patterson, Omar Jawdat, Edward J Kasarskis, Yaz Y Kisanuki, James Wymer, Christina Fournier, Ghazala Hayat, Daragh Heitzman, Catherine Lomen-Hoerth, Michael T Pulley, Stephen N Scelsa, David Walk, Stephen A Goutman, Christen Shoesmith, Zachary Simmons, Eric Sorenson, Lauren Elman, Matthew B Harms, Benjamin N Hoover, Rebecca Y Yun, Regina M Santella, Hiroshi Mitsumoto","doi":"10.1002/ana.78056","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The primary lateral sclerosis (PLS) consensus diagnostic criteria and functional rating scale (PLSFRS) were recently established to facilitate and optimize future PLS clinical trials. We examined the trajectory of the PLSFRS and other functional outcome measures and biomarkers in the PLS Natural History Study (PLS NHS) to understand their performance in this prospective cohort.</p><p><strong>Methods: </strong>The PLS NHS is a prospective, longitudinal, multicenter study of people living with PLS in different diagnostic categories: early (disease duration <2 years); probable (2-4 years); and definite PLS (4-15 years). PLSFRS scores and other functional outcome measures were collected at baseline, 3-, 6-, 9-, and 12-month follow-up visits. Baseline characteristics were compared between the groups. The slopes of the PLSFRS and other functional outcome measures over 12 months were examined in the overall cohort and subgroups using linear mixed-effect models. The associations between baseline characteristics and the rate of PLSFRS decline were analyzed with linear regression models.</p><p><strong>Results: </strong>A total of 76 participants were included: early (n = 6); probable (n = 26); and definite (n = 44) PLS. Baseline PLSFRS total scores were highest in the early PLS group, followed by the probable and definite PLS groups. In the overall cohort, the PLSFRS total score declined by 0.33 points/month (95% confidence interval [0.27-0.39], adjusted p < 0.05). The rate of decline was steepest in the early PLS group, followed by the probable and definite PLS groups. Baseline neurofilament light chain level was associated with the rate of PLSFRS decline over 1 year (p = 0.001).</p><p><strong>Interpretation: </strong>In PLS, the rate of functional decline, as measured by the PLSFRS total score, is faster during the early phase of the disease. Neurofilament light might serve as a prognostic biomarker in PLS. ANN NEUROL 2025.</p>","PeriodicalId":127,"journal":{"name":"Annals of Neurology","volume":" ","pages":""},"PeriodicalIF":7.7000,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Primary Lateral Sclerosis Natural History Study: Primary Lateral Sclerosis Functional Rating Scale and Other Outcomes Assessment.\",\"authors\":\"Ikjae Lee, Grace Jang, Ying Kuen Ken Cheung, Alexander V Sherman, Wendy S Johnston, Frank Diaz, J Americo M Fernandes, Ali A Habib, Nicholas J Maragakis, Sabrina Paganoni, Katherine Burke, Bjorn Oskarsson, Jaimin Shah, Lorne Zinman, Mary Kay Floeter, Senda Ajroud-Driss, Kelly Gwathmey, Terry Heiman-Patterson, Omar Jawdat, Edward J Kasarskis, Yaz Y Kisanuki, James Wymer, Christina Fournier, Ghazala Hayat, Daragh Heitzman, Catherine Lomen-Hoerth, Michael T Pulley, Stephen N Scelsa, David Walk, Stephen A Goutman, Christen Shoesmith, Zachary Simmons, Eric Sorenson, Lauren Elman, Matthew B Harms, Benjamin N Hoover, Rebecca Y Yun, Regina M Santella, Hiroshi Mitsumoto\",\"doi\":\"10.1002/ana.78056\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>The primary lateral sclerosis (PLS) consensus diagnostic criteria and functional rating scale (PLSFRS) were recently established to facilitate and optimize future PLS clinical trials. We examined the trajectory of the PLSFRS and other functional outcome measures and biomarkers in the PLS Natural History Study (PLS NHS) to understand their performance in this prospective cohort.</p><p><strong>Methods: </strong>The PLS NHS is a prospective, longitudinal, multicenter study of people living with PLS in different diagnostic categories: early (disease duration <2 years); probable (2-4 years); and definite PLS (4-15 years). PLSFRS scores and other functional outcome measures were collected at baseline, 3-, 6-, 9-, and 12-month follow-up visits. Baseline characteristics were compared between the groups. The slopes of the PLSFRS and other functional outcome measures over 12 months were examined in the overall cohort and subgroups using linear mixed-effect models. The associations between baseline characteristics and the rate of PLSFRS decline were analyzed with linear regression models.</p><p><strong>Results: </strong>A total of 76 participants were included: early (n = 6); probable (n = 26); and definite (n = 44) PLS. Baseline PLSFRS total scores were highest in the early PLS group, followed by the probable and definite PLS groups. In the overall cohort, the PLSFRS total score declined by 0.33 points/month (95% confidence interval [0.27-0.39], adjusted p < 0.05). The rate of decline was steepest in the early PLS group, followed by the probable and definite PLS groups. Baseline neurofilament light chain level was associated with the rate of PLSFRS decline over 1 year (p = 0.001).</p><p><strong>Interpretation: </strong>In PLS, the rate of functional decline, as measured by the PLSFRS total score, is faster during the early phase of the disease. Neurofilament light might serve as a prognostic biomarker in PLS. ANN NEUROL 2025.</p>\",\"PeriodicalId\":127,\"journal\":{\"name\":\"Annals of Neurology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":7.7000,\"publicationDate\":\"2025-09-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Neurology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/ana.78056\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/ana.78056","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的:最近建立了原发性侧索硬化(PLS)共识诊断标准和功能评定量表(PLSFRS),以促进和优化未来的PLS临床试验。我们在PLS自然历史研究(PLS NHS)中检查了PLSFRS和其他功能结果测量和生物标志物的轨迹,以了解它们在这一前瞻性队列中的表现。方法:PLS NHS是一项针对不同诊断类别PLS患者的前瞻性、纵向、多中心研究:早期(疾病持续时间)结果:共纳入76名参与者:早期(n = 6);可能(n = 26);早期PLS组的基线PLSFRS总分最高,其次是可能PLS组和明确PLS组。在整个队列中,PLSFRS总分下降了0.33分/月(95%置信区间[0.27-0.39],校正p)。解释:在PLS中,由PLSFRS总分测量的功能下降速度在疾病早期更快。神经丝光可能作为PLS. ANN NEUROL 2025的预后生物标志物。
Primary Lateral Sclerosis Natural History Study: Primary Lateral Sclerosis Functional Rating Scale and Other Outcomes Assessment.
Objective: The primary lateral sclerosis (PLS) consensus diagnostic criteria and functional rating scale (PLSFRS) were recently established to facilitate and optimize future PLS clinical trials. We examined the trajectory of the PLSFRS and other functional outcome measures and biomarkers in the PLS Natural History Study (PLS NHS) to understand their performance in this prospective cohort.
Methods: The PLS NHS is a prospective, longitudinal, multicenter study of people living with PLS in different diagnostic categories: early (disease duration <2 years); probable (2-4 years); and definite PLS (4-15 years). PLSFRS scores and other functional outcome measures were collected at baseline, 3-, 6-, 9-, and 12-month follow-up visits. Baseline characteristics were compared between the groups. The slopes of the PLSFRS and other functional outcome measures over 12 months were examined in the overall cohort and subgroups using linear mixed-effect models. The associations between baseline characteristics and the rate of PLSFRS decline were analyzed with linear regression models.
Results: A total of 76 participants were included: early (n = 6); probable (n = 26); and definite (n = 44) PLS. Baseline PLSFRS total scores were highest in the early PLS group, followed by the probable and definite PLS groups. In the overall cohort, the PLSFRS total score declined by 0.33 points/month (95% confidence interval [0.27-0.39], adjusted p < 0.05). The rate of decline was steepest in the early PLS group, followed by the probable and definite PLS groups. Baseline neurofilament light chain level was associated with the rate of PLSFRS decline over 1 year (p = 0.001).
Interpretation: In PLS, the rate of functional decline, as measured by the PLSFRS total score, is faster during the early phase of the disease. Neurofilament light might serve as a prognostic biomarker in PLS. ANN NEUROL 2025.
期刊介绍:
Annals of Neurology publishes original articles with potential for high impact in understanding the pathogenesis, clinical and laboratory features, diagnosis, treatment, outcomes and science underlying diseases of the human nervous system. Articles should ideally be of broad interest to the academic neurological community rather than solely to subspecialists in a particular field. Studies involving experimental model system, including those in cell and organ cultures and animals, of direct translational relevance to the understanding of neurological disease are also encouraged.